课题基金 / 基金详情

项目摘要

项目成果

MARA A SCHONBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Primary care physicians and nurse practitioners (herein referred to as primary care providers, PCPs) are increasingly being encouraged to take into account older adults' long-term (>5 years) prognosis when deciding whether or not to recommend medical interventions for older adults. One of the most common medical interventions for which PCPs are encouraged to take into account older adults' long-term prognosis is when deciding on cancer screening. It is estimated that 1,000 older adults need to be screened for breast (specific to women only) or colon cancer for one to avoid death from these cancers in 10 years. Due to this 10-year lag- time to benefit, guidelines recommend that adults with <10 year life expectancy not be screened for these cancers. The rationale is that these patients will not live long enough to experience the possible life-prolonging benefits of cancer screening. Instead, screening these patients only puts them at risk of the harms of cancer screening which include: anxiety resulting from false positive tests, overdiagnosis (detection of tumors that are of no threat), and complications from work-up or treatment of cancer. Despite this, many older adults with short life expectancy are screened for cancer. One reason for this is that PCPs avoid talking to older adults about stopping cancer screening. These discussions require consideration and often discussion of patient life expectancy and PCPs report feeling uncomfortable estimating and discussing prognosis with older adults. However, by avoiding these discussions, PCPs may be undermining their patients' ability to make informed decisions around cancer screening and other medical interventions. While there are tools available to help PCPs estimate patient prognosis, there is little information to guide PCPs on how to discuss stopping cancer screening and long-term prognosis with older adults. Therefore, in Aim 1 we plan to conduct focus groups and individual interviews with PCPs (community and academic) and individual interviews with adults 76 to 89 years with 5-10 year life expectancy to learn their thoughts, preferences, and suggestions for how PCPs should approach discussing stopping cancer screening and long-term prognosis with older adults. We will then use these data to develop strategies and guiding principles for PCPs to use for having these discussions and we will create scripts to suggest language for PCPs to use during these discussions. In Aim 2, we will provide 45 PCPs with the drafted scripts and prognostic information for 1-3 of their patients (goal to recruit 90 adults aged 76 to 89 years) before a clinic visit. We will interview PCPs after these visits to learn if the prognostic information was used and whether PCPs found the prognostic information and/or the guiding scripts useful. We will also interview older adults after these visits to learn their perceptions of these conversations and their decision making around cancer screening. There is great need for strategies for PCPs to use to discuss stopping cancer screening and long-term prognosis with older adults so that older adults may make more informed decisions about their care and avoid medical interventions that may only cause them harm.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research and mentoring program in shared decision making in the care of older adults
Research and mentoring program in shared decision making in the care of older adults
Research and mentoring program in shared decision making in the care of older adults
A prediction model to simultaneously estimate personal risk of breast cancer and death from other causes in women aged 55 and older
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: